Cargando…

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER

The aim of the present work is to compare drug survival and safety of infliximab, etanercept, and adalimumab (tumor necrosis factor [TNF] antagonists) in spondylarthritis (SpA) with those of rheumatoid arthritis (RA). To this purpose, we analysed the data in BIOBADASER (2000–2005), a drug registry l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carmona, Loreto, Gómez-Reino, Juan J
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526631/ https://www.ncbi.nlm.nih.gov/pubmed/16620398 http://dx.doi.org/10.1186/ar1941

Ejemplares similares

PReS-FINAL-2168: Comparison of safety and retention rate of TNF antagonist therapy in juvenile-onset and adult-onset ankylosing spondylitis: data from the spanish registry biobadaser 2.0
por: Sifuentes Giraldo, WA, et al.
Publicado: (2013)

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
por: Gomez-Reino, Juan J, et al.
Publicado: (2006)

Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
por: Moreno-Ramos, Manuel José, et al.
Publicado: (2022)

Correction to: Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
por: Moreno-Ramos, Manuel José, et al.
Publicado: (2022)

Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
por: Valero, Marta, et al.
Publicado: (2023)

Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
por: Valero, Marta, et al.
Publicado: (2023)

Subclinical Atherosclerosis Measure by Carotid Ultrasound and Inflammatory Activity in Patients with Rheumatoid Arthritis and Spondylarthritis
por: Rojas-Giménez, Marta, et al.
Publicado: (2022)

Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER
por: Bethencourt Baute, Juan José, et al.
Publicado: (2018)

Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry
por: Prior-Español, A., et al.
Publicado: (2021)

DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists
por: Navarro-Sarabia, Federico, et al.
Publicado: (2009)

Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis
por: Furuya, Hidekazu, et al.
Publicado: (2013)

Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
por: Lim, Heejin, et al.
Publicado: (2018)

Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register
por: Vela, Paloma, et al.
Publicado: (2020)

MRI Findings in Axial Psoriatic Spondylarthritis
por: Pascu, Loredana Sabina, et al.
Publicado: (2023)

Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis
por: Maneiro, Jose Ramon, et al.
Publicado: (2015)

Anti-carbamylated protein autoantibodies associated with mortality in Spanish rheumatoid arthritis patients
por: Vidal-Bralo, Laura, et al.
Publicado: (2017)

High Sodium Intake Is Associated With Self-Reported Rheumatoid Arthritis: A Cross Sectional and Case Control Analysis Within the SUN Cohort
por: Salgado, Eva, et al.
Publicado: (2015)

Comparative Persistence of the TNF Antagonists in Rheumatoid Arthritis – A Population-Based Cohort Study
por: Fisher, Anat, et al.
Publicado: (2014)

Progress in spondylarthritis. Spondyloarthritis: lessons from imaging
por: Maksymowych, Walter P
Publicado: (2009)

Axial spondylarthritis following COVID-19 infection
por: Gopalarathinam, Rajesh, et al.
Publicado: (2023)

The Effect of TNF-α on CHD and the Relationship between TNF-α Antagonist and CHD in Rheumatoid Arthritis: A Systematic Review
por: Qian, Yezhou, et al.
Publicado: (2022)

Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis
por: Lories, Rik JU, et al.
Publicado: (2009)

Progress in spondylarthritis. Progress in studies of the genetics of ankylosing spondylitis
por: Brown, Matthew A
Publicado: (2009)

Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists
por: Finckh, Axel, et al.
Publicado: (2012)

Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial
por: Durez, Patrick, et al.
Publicado: (2014)

Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: a collaborative matched cohort study from Sweden and Denmark
por: Secher, Anne Emilie Pape, et al.
Publicado: (2022)

Attitudes of patients with spondylarthritis or rheumatoid arthritis regarding biological treatment during COVID-19 pandemic: A multi-center, phone-based, cross-sectional study
por: Zateri, Coskun, et al.
Publicado: (2021)

Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study
por: Suarez-Gestal, Marian, et al.
Publicado: (2010)

Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-α antagonists
por: Germano, Valentina, et al.
Publicado: (2014)

Progress in spondylarthritis. Immunopathogenesis of spondyloarthritis: which cells drive disease?
por: Melis, Lode, et al.
Publicado: (2009)

Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis
por: Bethge, Johannes, et al.
Publicado: (2017)

MicroRNAs in Axial Spondylarthritis: an Overview of the Recent Progresses in the Field with a Focus on Ankylosing Spondylitis and Psoriatic Arthritis
por: Motta, Francesca, et al.
Publicado: (2021)

Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis
por: Lopez-Rodriguez, Rosario, et al.
Publicado: (2018)

Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure
por: Kekow, Joern, et al.
Publicado: (2012)

Plasma leptin and neuropeptide Y concentrations in patients with rheumatoid arthritis treated with infliximab, a TNF-α antagonist
por: Kopec-Medrek, Magdalena, et al.
Publicado: (2011)

Treating psoriatic arthritis: how effective are TNF antagonists?
por: Gottlieb, Alice B, et al.
Publicado: (2004)

Monitoring the efficacy of tumor necrosis factor alpha antagonists in the treatment of Ankylosing spondylarthritis: a pilot study based on MR relaxometry technique
por: Lin, Mingui, et al.
Publicado: (2021)

Better Clinical Results in Rheumatoid Arthritis Patients Treated Under a Multidisciplinary Care Model When Compared with a National Rheumatoid Arthritis Registry
por: Santos-Moreno, Pedro, et al.
Publicado: (2022)

Bone and TNF in rheumatoid arthritis: clinical implications
por: Manara, Maria, et al.
Publicado: (2015)

Interleukin-1 associations in inflammatory bowel disease and the enteropathic seronegative spondylarthritis
por: Vounotrypidis, Periklis, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_re7p1u4tk4eqto7a8k2gpttorq